Abstract

Lysosomal dysfunction has been implicated both pathologically and genetically in neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease (PD). Lysosomal gene deficiencies cause lysosomal storage disorders, many of which involve neurodegeneration. Heterozygous mutations of some of these genes, such as GBA1, are associated with PD. CTSD is the gene encoding Cathepsin D (CTSD), a lysosomal protein hydrolase, and homozygous CTSD deficiency results in neuronal ceroid-lipofuscinosis, which is characterized by the early onset, progressive neurodegeneration. CTSD deficiency was also associated with deposition of α-synuclein aggregates, the hallmark of PD. However, whether partial deficiency of CTSD has a role in the late onset progressive neurodegenerative disorders, including PD, remains unknown. Here, we generated cell lines harboring heterozygous nonsense mutations in CTSD with genomic editing using the zinc finger nucleases. Heterozygous mutation in CTSD resulted in partial loss of CTSD activity, leading to reduced lysosomal activity. The CTSD mutation also resulted in increased accumulation of intracellular α-synuclein aggregates and the secretion of the aggregates. When α-synuclein was introduced in the media, internalized α-synuclein aggregates accumulated at higher levels in CTSD+/− cells than in the wild-type cells. Consistent with these results, transcellular transmission of α-synuclein aggregates was increased in CTSD+/− cells. The increased transmission of α-synuclein aggregates sustained during the successive passages of CTSD+/− cells. These results suggest that partial loss of CTSD activity is sufficient to cause a reduction in lysosomal function, which in turn leads to α-synuclein aggregation and propagation of the aggregates.

Highlights

  • Pathological examinations of patient tissues have exhibited that protein aggregates, such as amyloid beta (Aβ), tau and α-synuclein aggregates, spread to larger brain regions as disease progresses.[17]

  • We were not able to generate a clone with mutations in both copies. This is consistent with the previous transgenic mouse study, in which Cathepsin D (CTSD)-null mice were lethal

  • We showed that experimental haploinsufficiency of CTSD resulted in the reduction of lysosomal functions, impaired α-synuclein catabolism, increased α-synuclein secretion and decreased degradation of internalized α-synuclein, leading to increased cell-to-cell transmission of α-synuclein aggregates

Read more

Summary

Introduction

Pathological examinations of patient tissues have exhibited that protein aggregates, such as amyloid beta (Aβ), tau and α-synuclein aggregates, spread to larger brain regions as disease progresses.[17]. Mounting evidence have suggested that lysosomal function is important for the clearance of the transferred aggregates in recipient neurons during cell-to-cell aggregate transmission.[31]. This has been extensively studied in cell culture models for α-synuclein transmission. Mutations in genes encoding lysosomal catabolic enzymes and transporters manifest excessive deposition of the enzyme substrates in various organs.[34] Though different LSDs show different symptoms, most of LSD patients exhibit neurological symptoms such as mental retardation, motor dysfunction and progressive neurodegeneration, as well as specific pathological changes in the nervous system.[35,36] In addition, some of progressive neurodegenerative disorders such as AD, PD and Huntington’s disease show similar pathological features with LSD: accumulations of endosomal and autophagosomal vesicles and undegraded macromolecules, and inflammatory responses in brain.[16]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call